Elsevier

Molecular and Cellular Neuroscience

Volume 56, September 2013, Pages 475-486
Molecular and Cellular Neuroscience

Fused in sarcoma (FUS): An oncogene goes awry in neurodegeneration

https://doi.org/10.1016/j.mcn.2013.03.006Get rights and content

Abstract

Fused in sarcoma (FUS) is a nuclear DNA/RNA binding protein that regulates different steps of gene expression, including transcription, splicing and mRNA transport. FUS has been implicated in neurodegeneration, since mutations in FUS cause familial amyotrophic lateral sclerosis (ALS-FUS) and lead to the cytosolic deposition of FUS in the brain and spinal cord of ALS-FUS patients. Moreover, FUS and two related proteins of the same protein family (FET family) are co-deposited in cytoplasmic inclusions in a subset of patients with frontotemporal lobar degeneration (FTLD-FUS). Cytosolic deposition of these otherwise nuclear proteins most likely causes the loss of a yet unknown essential nuclear function and/or the gain of a toxic function in the cytosol. Here we summarize what is known about the physiological functions of the FET proteins in the nucleus and cytoplasm and review the distinctive pathomechanisms that lead to the deposition of only FUS in ALS-FUS, but all three FET proteins in FTLD-FUS. We suggest that ALS-FUS is caused by a selective dysfunction of FUS, while FTLD-FUS may be caused by a dysfunction of the entire FET family. This article is part of a Special Issue entitled ‘RNA and splicing regulation in neurodegeneration’.

Introduction

FUS, also known as Translocated in liposarcoma (TLS), was identified about 20 years ago as a fusion oncogene in human myxoid liposarcomas (Crozat et al., 1993, Rabbitts et al., 1993). In these cancers, an aberrant chromosomal translocation fuses the N-terminus of FUS to a transcription factor, such as CHOP, giving rise to a fusion oncogene (Crozat et al., 1993, Rabbitts et al., 1993). In the following decade, research on FUS was mainly focused on these fusion oncogenes and the mechanisms by which they cause oncogenic transformation (Kovar, 2011). About 15 years later, researchers interested in neurodegeneration suddenly took an interest in FUS, when mutations in FUS were reported to cause familial ALS and deposition of FUS in pathological protein inclusions (Kwiatkowski et al., 2009, Vance et al., 2009). Shortly afterwards, FUS inclusions were also found in the brains of a subset of FTLD patients, however in the absence of FUS mutations (Munoz et al., 2009, Neumann et al., 2009a, Neumann et al., 2009b). Insoluble protein deposits are observed in almost all neurodegenerative disorders, and the disease-characterizing proteinaceous components of these inclusions provided tremendous insights into the underlying disease mechanisms (Haass and Selkoe, 2007).

Section snippets

ALS and FTLD: related yet distinct neurodegenerative disorders

ALS and FTLD are considered to be related disorders with overlapping clinical symptoms, genetics and neuropathology. ALS, also known as Lou Gehrig's disease, is the most frequent motor neuron disease and is caused by degeneration of upper and lower motor neurons (Kiernan et al., 2011). The most prominent clinical symptom is muscle weakening and atrophy throughout the body. Due to progressive muscle wasting, ALS patients experience increasing difficulties in moving, swallowing, speaking and

FUS: a multifunctional nuclear protein

FUS is a 526 amino acid multidomain protein with an N-terminal transcriptional activation domain, multiple nucleic acid binding domains and a C-terminal nuclear localization signal (NLS) (Fig. 2a). The N-terminal SYGQ-rich domain functions as a potent transcriptional activation domain when fused to the DNA binding domain of other transcription factors (Prasad et al., 1994, Zinszner et al., 1994). This is the case in the above mentioned fusion oncogenes, e.g. FUS-CHOP in myxoid liposarcoma (

FET family proteins

FUS is a member of a protein family called the FET family (Tan and Manley, 2009). The other two FET family members, Ewing sarcoma protein (EWS) and TATA binding protein-associated factor 15 (TAF15), have the same domain structure as FUS (Fig. 2d) and are also imported into the nucleus via a PY-NLS (Lee et al., 2006, Marko et al., 2012, Zakaryan and Gehring, 2006). Like FUS, EWS and TAF15 are components of fusion oncogenes in a variety of cancers and have a well-established function in

Physiological roles of the FET family proteins

FUS and the FET family proteins are involved in multiple steps of DNA/RNA processing, including nuclear processes (e.g. transcription, pre-mRNA splicing and DNA repair) and cytosolic processes (e.g. mRNA transport for local translation). It is therefore not surprising that alterations in the FET proteins' subcellular localization and their sequestration into protein aggregates have deleterious consequences for cellular functions.

FET proteins in DNA damage response

Soon after its discovery as a fusion oncogene, FUS was found to be identical to the POMp75 protein, which has DNA homologous pairing activity and is important for the repair of DNA double strand breaks (Baechtold et al., 1999, Bertrand et al., 1999). FUS binds to denatured single-stranded DNA and promotes its annealing to complementary single stranded DNA and d-loop formation (Baechtold et al., 1999) (Fig. 3a). Moreover, EWS was shown to regulate DNA damage-induced alternative splicing events (

FET proteins in transcriptional regulation

Initial clues about the role of the FET proteins in gene transcription came from the observation that their N-terminal SYGQ-rich domain functions as a potent transcriptional activation domain in oncogenic fusion proteins (Bertolotti et al., 1999, May et al., 1993, Prasad et al., 1994, Zinszner et al., 1994). Moreover, the Drosophila homologue of FUS, named Cabeza (CAZ) or Sarcoma-associated RNA binding fly homologue (SARFH), was found to localize to areas of active transcription in polytene

FET proteins in pre-mRNA splicing and physiological splice targets

Around the same time that the FET proteins were identified as transcriptional activators in oncogenic fusion proteins, they were also recognized to be important splicing regulators. All three FET proteins were co-purified with the human spliceosome (Rappsilber et al., 2002, Zhou et al., 2002), different pre-mRNA splicing complexes (Calvio et al., 1995, Kameoka et al., 2004, Wu and Green, 1997) and the spliceosomal Sm core (Hackl and Luhrmann, 1996) (Fig. 3c). More recently, TAF15 and FUS were

Functions of FUS outside the nucleus

FUS not only regulates gene expression in the nucleus, but also exerts important functions in the cytoplasm. FUS has been shown to continuously shuttle between the nucleus and the cytoplasm (Zinszner et al., 1997) and therefore might play a role in mRNA export (Fig. 3e). It is still unknown if export is mediated by RNA or by specific nuclear export receptors. Whether EWS and TAF15 undergo similar shuttling and what roles they might play in the cytoplasm has not been investigated.

In neurons, FUS

Pathomechanisms in FTLD-FUS and ALS-FUS

A subset of FTLD and ALS cases (FTLD-FUS and ALS-FUS) are characterized by FUS-immunoreactive neuronal and glial inclusions (Mackenzie et al., 2011a, Mackenzie et al., 2011b, Neumann et al., 2009a). FUS inclusions are typically observed in the cytoplasm and less frequently in the nucleus of neuronal and glial cells. Moreover, FUS pathology is often accompanied by a reduction of nuclear FUS staining, consistent with the idea that defects in nuclear import of FUS contribute to FUS pathology (

FTLD-FUS: co-deposition of FET proteins and Transportin caused by defects in arginine methylation

In contrast to ALS-FUS, FTLD-FUS is usually not associated with mutations in FUS (Neumann et al., 2009a, Snowden et al., 2011, Urwin et al., 2010), so there is no obvious explanation for the cytoplasmic deposition of FUS in these cases. Moreover, EWS, TAF15 and Transportin are co-deposited along with FUS in neuronal cytoplasmic inclusions in FTLD-FUS patients (Table 1) and inclusion-bearing cells often show reduced nuclear staining of all three FET proteins (Brelstaff et al., 2011, Davidson et

ALS-FUS: selective deposition of FUS caused by FUS mutations

In contrast to FTLD-FUS, ALS-FUS cases show a selective deposition of FUS, i.e. EWS, TAF15 and Transportin are not co-deposited in FUS-positive inclusions (Neumann et al., 2011, Troakes et al., in press) (Table 1). This selective nuclear import defect in ALS-FUS can be explained by a point mutation in the FUS gene that produces a defective PY-NLS or a truncated FUS protein lacking the entire PY-NLS (Fig. 2a). This impairs Transportin binding and nuclear import of FUS and leads to its

Stress granules and p62 — further hits are required for pathological FUS deposition

The nuclear import defects described above presumably are an important first step in the pathological cascade, but are not sufficient for aggregation and deposition of cytosolically mislocalized FUS/FET proteins. The presence of stress granule marker proteins and components of the protein degradation machinery in cytoplasmic FUS inclusions (Table 1) suggests that a second hit, such as cellular stress and/or defects in protein degradation, may be involved in the formation of pathological protein

Intranuclear FUS inclusions in neurodegenerative diseases

Although FUS-immunoreactive inclusions in ALS/FTLD-FUS cases are mostly found in the cytoplasm, they are occasionally observed in the nucleus as well (Lashley et al., 2011, Mackenzie et al., 2011a, Mackenzie et al., 2011b, Neumann et al., 2009a). Nuclei containing these intranuclear inclusions often show reduced amounts of FUS in the nucleoplasm, suggesting that sequestration of FUS in intranuclear inclusions interferes with the protein's normal localization and function. How intranuclear FUS

Acknowledgments

We thank Eva Bentmann, Dieter Edbauer, Denise Orozco, Bettina Schmid and Marc Suarez-Calvet for critically reading the manuscript, Claudia Abou-Ajram for suggestions on figures and Manuela Neumann for comments regarding neuropathology. This work was supported by the Competence Network for Neurodegenerative Diseases (KNDD) of the Bundesministerium für Bildung und Forschung (BMBF) and the Consortium of Centers of Excellence in Neurodegenerative Brain Diseases (CoEN) to C.H. The research leading

References (157)

  • M. Dejesus-Hernandez et al.

    Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS

    Neuron

    (2011)
  • H. Doi et al.

    The RNA-binding protein FUS/TLS is a common aggregate-interacting protein in polyglutamine diseases

    Neurosci. Res.

    (2010)
  • H. Doi et al.

    RNA-binding protein TLS is a major nuclear aggregate-interacting protein in huntingtin exon 1 with expanded polyglutamine-expressing cells

    J. Biol. Chem.

    (2008)
  • D. Dormann et al.

    TDP-43 and FUS: a nuclear affair

    Trends Neurosci.

    (2011)
  • K. Fronz et al.

    Arginine methylation of the nuclear poly(a) binding protein weakens the interaction with its nuclear import receptor, transportin

    J. Biol. Chem.

    (2011)
  • K. Fronz et al.

    Promiscuous modification of the nuclear poly(A)-binding protein by multiple protein-arginine methyltransferases does not affect the aggregation behavior

    J. Biol. Chem.

    (2008)
  • R. Fujii et al.

    The RNA binding protein TLS is translocated to dendritic spines by mGluR5 activation and regulates spine morphology

    Curr. Biol.

    (2005)
  • I. Gijselinck et al.

    A C9orf72 promoter repeat expansion in a Flanders–Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study

    Lancet Neurol.

    (2012)
  • W. Hackl et al.

    Molecular cloning and subcellular localisation of the snRNP-associated protein 69KD, a structural homologue of the proto-oncoproteins TLS and EWS with RNA and DNA-binding properties

    J. Mol. Biol.

    (1996)
  • M. Hallier et al.

    The transcription factor Spi-1/PU.1 interacts with the potential splicing factor TLS

    J. Biol. Chem.

    (1998)
  • Y. Iko et al.

    Domain architectures and characterization of an RNA-binding protein, TLS

    J. Biol. Chem.

    (2004)
  • T. Kampers et al.

    RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments

    FEBS Lett.

    (1996)
  • Y. Kanai et al.

    Kinesin transports RNA: isolation and characterization of an RNA-transporting granule

    Neuron

    (2004)
  • M. Kato et al.

    Cell-free formation of RNA granules: low complexity sequence domains form dynamic fibers within hydrogels

    Cell

    (2012)
  • M.C. Kiernan et al.

    Amyotrophic lateral sclerosis

    Lancet

    (2011)
  • O.D. King et al.

    The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease

    Brain Res.

    (2012)
  • V.I. Korolchuk et al.

    Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems

    FEBS Lett.

    (2010)
  • B.J. Lee et al.

    Rules for nuclear localization sequence recognition by karyopherin beta 2

    Cell

    (2006)
  • M. Leichter et al.

    A fraction of the transcription factor TAF15 participates in interactions with a subset of the spliceosomal U1 snRNP complex

    Biochim. Biophys. Acta

    (2011)
  • A. Lerga et al.

    Identification of an RNA binding specificity for the potential splicing factor TLS

    J. Biol. Chem.

    (2001)
  • X. Li et al.

    TEThered to Runx: novel binding partners for runx factors

    Blood Cells Mol. Dis.

    (2010)
  • I.R. Mackenzie et al.

    FET proteins in frontotemporal dementia and amyotrophic lateral sclerosis

    Brain Res.

    (2012)
  • I.R. Mackenzie et al.

    TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia

    Lancet Neurol.

    (2010)
  • M. Marko et al.

    Domains involved in TAF15 subcellular localisation: dependence on cell type and ongoing transcription

    Gene

    (2012)
  • M. Meissner et al.

    Proto-oncoprotein TLS/FUS is associated to the nuclear matrix and complexed with splicing factors PTB, SRm160, and SR proteins

    Exp. Cell Res.

    (2003)
  • Y. Mizuno et al.

    Immunoreactivities of p62, an ubiqutin-binding protein, in the spinal anterior horn cells of patients with amyotrophic lateral sclerosis

    J. Neurol. Sci.

    (2006)
  • M.K. Andersson et al.

    The multifunctional FUS, EWS and TAF15 proto-oncoproteins show cell type-specific expression patterns and involvement in cell spreading and stress response

    BMC Cell Biol.

    (2008)
  • N. Aoki et al.

    Localization of fused in sarcoma (FUS) protein to the post-synaptic density in the brain

    Acta Neuropathol.

    (2012)
  • K. Arimoto et al.

    Formation of stress granules inhibits apoptosis by suppressing stress-responsive MAPK pathways

    Nat. Cell Biol.

    (2008)
  • D. Baumer et al.

    Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations

    Neurology

    (2010)
  • A. Bertolotti et al.

    The N-terminal domain of human TAFII68 displays transactivation and oncogenic properties

    Oncogene

    (1999)
  • A. Bertolotti et al.

    hTAF(II)68, a novel RNA/ssDNA-binding protein with homology to the pro-oncoproteins TLS/FUS and EWS is associated with both TFIID and RNA polymerase II

    EMBO J.

    (1996)
  • A. Bertolotti et al.

    EWS, but not EWS-FLI-1, is associated with both TFIID and RNA polymerase II: interactions between two members of the TET family, EWS and hTAFII68, and subunits of TFIID and RNA polymerase II complexes

    Mol. Cell. Biol.

    (1998)
  • P. Bertrand et al.

    Human POMp75 is identified as the pro-oncoprotein TLS/FUS: both POMp75 and POMp100 DNA homologous pairing activities are associated to cell proliferation

    Oncogene

    (1999)
  • D.A. Bosco et al.

    Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules

    Hum. Mol. Genet.

    (2010)
  • J. Brelstaff et al.

    Transportin1: a marker of FTLD-FUS

    Acta Neuropathol.

    (2011)
  • C.G. Burd et al.

    Conserved structures and diversity of functions of RNA-binding proteins

    Science

    (1994)
  • C. Calvio et al.

    Identification of hnRNP P2 as TLS/FUS using electrospray mass spectrometry

    RNA

    (1995)
  • T. Carvalho et al.

    The spinal muscular atrophy disease gene product, SMN: a link between snRNP biogenesis and the Cajal (coiled) body

    J. Cell Biol.

    (1999)
  • H.A. Chansky et al.

    Oncogenic TLS/ERG and EWS/Fli-1 fusion proteins inhibit RNA splicing mediated by YB-1 protein

    Cancer Res.

    (2001)
  • Cited by (103)

    • Chemistry and biology of enzymes in protein glutathionylation

      2023, Current Opinion in Chemical Biology
    View all citing articles on Scopus
    View full text